Benefits
4% improvement in aerobic time trial performance
In healthy untrained young men, ActivAMP at 450 mg/day for 4 weeks produced approximately 4% faster 20 km cycle ergometer time trial compared to placebo. Muscle biopsies revealed greater oxygen flux in muscle tissue at rest, supporting the mechanistic basis. A meaningful performance edge for endurance athletes, particularly in untrained or recreationally active populations.
Body composition improvement in overweight adults
In overweight adult men and women, ActivAMP at 450 mg/day for 16 weeks improved body composition vs placebo. Supports the broader 'master metabolic regulator' positioning across weight and performance applications.
First muscle-biopsy-validated AMPK activator
The aerobic performance trial is the first nutraceutical-industry study to demonstrate AMPK activation in a human trial through muscle biopsy, a substantially higher standard than blood biomarker or surrogate measurement. Confirms ActivAMP's mechanism operates at the tissue level where it matters for metabolic and performance outcomes.
Glucose uptake and fat oxidation support
Preclinical research established that ActivAMP improves glucose uptake in muscle tissue and promotes utilization of fat as energy. The human trial confirmed reductions in leptin and blood glucose levels after 4-week supplementation. Mechanism is consistent with AMPK's documented metabolic effects across pharmaceutical research.
Mitochondrial biogenesis support
AMPK activation drives mitochondrial biogenesis — increasing the number and efficiency of mitochondria in muscle tissue. This mechanism underlies exercise-induced adaptations and is the basis for ActivAMP's positioning as a 'metabolic conditioning' ingredient. Higher mitochondrial density supports both endurance performance and metabolic flexibility.
Reduced fatigue and physical performance support
A randomized double-blind placebo-controlled trial of gypenoside-L-containing Gynostemma pentaphyllum extract specifically evaluated fatigue and physical performance outcomes. Effects on subjective fatigue ratings and exercise performance support the broader ActivAMP positioning beyond weight management.
Traditional Chinese medicine precedent
Gynostemma pentaphyllum (jiaogulan) has been used in traditional Chinese medicine for centuries as a tonic herb for energy, longevity, and general well-being. Often called 'southern ginseng' due to similar perceived effects. The traditional use precedent supports the long-term safety profile that modern clinical trials have continued to validate.
Mechanism of action
AMP-activated protein kinase (AMPK) activation
AMPK is the 'master metabolic regulator' — the cellular sensor that detects energy depletion and triggers metabolic adaptations. AMPK activation increases glucose uptake into muscle, fat oxidation, mitochondrial biogenesis, and reduces lipogenesis. The same target activated by exercise and the metformin diabetes medication. ActivAMP's gypenoside saponins activate this pathway pharmacologically.
Glucose transporter (GLUT4) translocation
AMPK activation drives translocation of GLUT4 (the insulin-responsive glucose transporter) to the muscle cell membrane — increasing glucose uptake even in insulin-resistant states. Mechanism parallels exercise-induced glucose uptake, explaining the reductions in fasting blood glucose seen in the human trial.
Fatty acid oxidation upregulation
AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and de-inhibiting carnitine palmitoyltransferase 1 (CPT1). This shifts metabolism toward fatty acid oxidation — using fat as fuel rather than storing it. Provides the molecular basis for the body composition improvements in overweight adults.
PGC-1α mediated mitochondrial biogenesis
AMPK activates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), the master regulator of mitochondrial biogenesis. Increased mitochondrial number and function supports endurance performance (more oxygen flux for ATP production) and metabolic flexibility (better fat oxidation capacity).
Leptin and adipokine modulation
The 4-week aerobic performance trial documented reductions in serum leptin — an adipocyte hormone that signals fat mass status to the brain. Elevated leptin in obesity contributes to leptin resistance and metabolic dysfunction. ActivAMP's leptin reduction is consistent with broader metabolic improvement.
Clinical trials
Double-blind randomized placebo-controlled trial of ActivAMP at 450 mg/day vs placebo for 16 weeks in overweight adults. Published in Journal of Human Nutrition and Dietetics 2022;35:583-589 (doi: 10.1111/jhn.12936). Authors: Rao A, Clayton P, Briskey D. Funded by Gencor Pacific.
Overweight adult men and women. 16-week intervention.
ActivAMP at 450 mg/day produced significant body composition improvements vs placebo over 16 weeks. Establishes the body weight management application that remains a primary commercial positioning. The dose used here was subsequently validated in the aerobic performance trial — supporting 450 mg/day as the cross-application clinical dose.
Double-blind randomized placebo-controlled crossover trial in healthy untrained young men. 450 mg/day ActivAMP vs placebo for 4 weeks with 4-week washout. Muscle, plasma, and serum samples collected. First nutraceutical-industry trial demonstrating human AMPK activation via muscle biopsy. Registered ACTRN12617001610325. Published 2023 in Nutrients.
16 healthy untrained young men. 4-week crossover protocol with 4-week washout.
ActivAMP at 450 mg/day improved 20 km time trial performance on cycle ergometer by approximately 4% vs placebo. Muscle biopsies revealed greater oxygen flux in muscle tissue at rest and AMPK phosphorylation increase. Significant reductions in serum leptin and blood glucose. First-of-its-kind muscle biopsy AMPK validation in a supplement trial.
Randomized double-blind placebo-controlled trial evaluating gypenoside-L-containing Gynostemma pentaphyllum extract for fatigue and physical performance outcomes. Published 2023 by Ahn Y et al. Distinct from the ActivAMP-specific trials but informs the broader Gynostemma class evidence for the Saanroo-licensed extract.
Healthy adults. Multi-week intervention.
Gypenoside-L-containing Gynostemma extract improved fatigue and physical performance vs placebo. Supports the broader Saanroo positioning of ActivAMP across exercise, fatigue, and metabolic applications. Specific gypenoside content matters for efficacy — generic Gynostemma products vary widely in saponin content and clinical activity.